Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach
Executive Summary
As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.
You may also be interested in...
Lilly's Carroll Talks Innovation, Partnering And Business Development Strategy
Eli Lilly Senior VP-Corporate Business Development Darren Carroll weighed in on pharmaceutical innovation, biotech valuations and the rising bar for external innovation during an interview at the J.P. Morgan Healthcare conference.
Better Living Through Chemistry: Biopharma Investors Weigh In
In START UP’s third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare diseases are top investment targets. Their skepticism about asset-based financing has grown, however, even as new twists on the model emerge.
Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly
Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.